Ben Lamm | Sourcery Summary

1. Key Themes

De-Extinction as Civilization-Scale Technology

Colossal is not positioning itself as a traditional biotech or conservation play — it's staking a claim as a "civilization tech" company, a newly coined category for technologies with planetary-scale impact. Ben draws a direct line from genome engineering to synthetic biology to the future programming of life itself.

"The ability to preserve, engineer and direct life on a planetary scale, in all species, I think is a pretty important skillset for humanity." 00:14:51

Speed of Editing as the Real Moat

The 30-day creation of 100% healthy woolly mice with the most multiplex edits ever delivered simultaneously was treated as a cute story by the press, but Ben views it as the proof point that the entire end-to-end pipeline works — and the speed is the signal.

"We had 100% healthy mice born with exactly the predicted phenotypes, with the most multiplex edited, delivered at one time ever. And we did it in 30 days. So the 30-day part got lost when we announced the woolly mice." 00:00:21

Vertical Integration as Competitive Strategy

Colossal has deliberately built or acquired every layer of the stack — from ancient DNA extraction to cloning infrastructure to AI — rather than outsourcing. The acquisition of Viagen (80% cloning efficiency vs. the industry's 2%) is a clear example of buying a critical chokepoint.

"Viagen had cloning efficiencies at 80%, most people are at two percent. And so it made sense for us to say, we need to buy them and bolt them on from a vertical integration perspective." 00:24:01

The Business Model Is Still Being Discovered — and That's a Feature

Colossal doesn't have a fixed business model, and Ben treats this as a sign of optionality, not a weakness. Three months before the interview, an entirely new use case appeared: a fabric supplier needing to 5x production of an ethically harvested animal fiber they're currently buying at billions of dollars.

"We don't know what we don't know even about the business model... Three months ago, we didn't know about that. And now we're working on coming up with a solution to help them solve that." 00:15:40 / 00:19:16

Invasive Species as a Massive, Underappreciated Revenue Opportunity

Invasive species is a $500 billion global problem. Colossal's gene drive technology could eradicate the screwworm in 6-7 months vs. a decade and $1.5 billion under current government programs — but the regulatory pathway is the bottleneck, not the technology.

"Our solution, which is already made, could eradicate the entire problem in every model that we've done in six to seven months. So we could save a decade in billions of dollars for taxpayers." 00:33:51

AI Convergence with Biology Is Creating a Pre-Cambrian Explosion of Drugs

Ben sees AI and synthetic biology converging into something that will reshape human healthcare — not through general-purpose models but through narrowly focused biological AI trained on evolutionary data. Astromech, Colossal's spinout, is the embodiment of this thesis.

"You're going to see this pre-Cambrian explosion of new drugs and new therapies that all come from AI-assisted drug design discovery." 00:20:30

Capital Efficiency Signal: Every Round 2x Oversubscribed

Every single financing round has been more than 2x oversubscribed, including a round that was targeted at $200M and closed at $400M. Ben reads this as mispricing their own valuation — a rare admission that has implications for future rounds.

"I think we've completely mispriced every single round of capital because every single round of capital has been more than two X oversubscribe. So what I hear from that is we're cheap." 00:43:23

Inspiration as a Core KPI, Not a Nice-to-Have

From day one, Ben told investors that inspiration must be as important as value creation. The brand strategy — "Harvard meets MTV" — is a deliberate, operationalized cultural architecture, not a marketing afterthought.

"We told our investors this from day one, that inspiration needs to be as important as value creation. And you need to be on board with that." 00:38:43

The Digital Twin of Nature: Ben's Highest-Conviction Prediction

Ben's hottest take is that AI will converge to produce a real-time digital twin of all of nature — a prediction model for the entire biosphere that allows humanity to understand the downstream consequences of every decision before it is made.

"I think AI is going to converge and we are going to build a digital twin of nature... We're going to understand in real time how nature is affected by every decision that we make." 00:06:06

2. Contrarian Perspectives

De-Extinction Is Not a Replacement for Conservation — and Conservation Is Losing

Rather than defending the conservation establishment, Ben acknowledges it is failing and argues that de-extinction is the necessary technological supplement. He even gets conservation insiders to admit the status quo isn't working.

"If you spend time with that community and you ask them, are we as humanity as a whole with current modern conservation techniques winning the fight to save species? And they will all tell you no." 00:30:13

Not Having a Biology Background Is an Advantage, Not a Disqualifier

Ben explicitly says he "couldn't be more qualified" to run Colossal precisely because he has no biology background — he applies a systems-thinking, first-principles software approach to a domain where academic tunnel vision and institutional politics typically dominate.

"Having zero background in biology and biotech, I couldn't be more qualified to run this company... Extinction is a systems model, genetic engineering is a systems model." 00:35:52

Open Sourcing Powerful Genome Technologies Is the Right Call, Despite Risk of Bad Actors

Most would argue keeping dual-use biological technologies proprietary is the responsible path. Ben takes the opposite position: the positive use cases outweigh the misuse risk, and the precedent of suppressing technologies in fear of bad actors is a losing strategy.

"That doesn't mean that we shouldn't engineer them and do and make them so that people can do good with them. I'm an eternal optimist. I believe that we as a species will do more good with them than that." 00:27:52

General-Purpose AI Models Are Not Useful for Frontier Biology — You Have to Build Your Own

Against the prevailing assumption that large foundation models (OpenAI, Claude) can serve any domain, Ben reports that they were simply not helpful for Colossal's actual work and the company had to build bespoke systems.

"In the early days, things like OpenAI and Claude and others weren't super helpful to our company because it turns out that Opus doesn't do like an ancestral state reconstruction of a genome and doesn't build comparative genomics models. So we had to go build all of that." 00:47:48

Heavily Capitalized Direct Air Capture Solutions Are "Dumb" Infrastructure Investments

Ben briefly but sharply challenges the trillion-dollar climate infrastructure narrative, suggesting that locking in direct air capture systems creates tech debt that the next generation will inherit — and that biology-based solutions are cleaner.

"A lot of the direct air capture carbon systems and other ways that we're trying to solve climate are dumb... If we invest a trillion dollars in that infrastructure globally and we hand it to our kids, our kids are going to have this tech debt that comes with that." 00:37:40

3. Companies Identified

Colossal Biosciences

De-extinction and genome engineering company working on reviving the woolly mammoth, dire wolf, and thylacine, while developing genome engineering tools applicable to invasive species biocontrol, endangered species cloning, and human healthcare. At a $12B valuation with $635M raised, every round 2x oversubscribed. Ben views it as one of the most undervalued companies in the world given its potential to engineer life at planetary scale.

"I do think that we are one of the most undervalued companies in the world. The ability to preserve, engineer and direct life on a planetary scale, in all species, I think is a pretty important skillset for humanity." 00:14:24

Astromech

Colossal spinout using a narrowly focused AI model trained on evolutionary genomic data to identify why certain species have conserved genomic regions that suppress cancer and resist disease — with applications to cancer drug design, bird flu prediction, and therapeutic development. Recently raised capital and may be raising again.

"It's using AI to build — it's a very focused model. So it doesn't need the breadth that a lot of these other models need... It's looking at evolutionary trends to understand why over evolutionary trends do certain animals have certain conserved regions of the genome that prevent things like cancer." 00:00:35

Viagen

The dominant animal cloning company in the U.S., operating at 80% cloning efficiency versus an industry norm of approximately 2%. Acquired by Colossal to vertically integrate their endangered species cloning, biobanking, and bio vault capabilities.

"Viagen had cloning efficiencies at 80%, most people are at two percent. And so it made sense for us to say, we need to buy them and bolt them on from a vertical integration perspective." 00:24:01

Weta Workshop

Peter Jackson's New Zealand-based special effects and animatronics company. Built Colossal's full-scale animatronic dire wolf installation and the lab's woolly mammoth display — used by Colossal to make science visceral and instagrammable for visitors and the public.

"We can thank Weta from New Zealand. If you're a fan of Peter Jackson, you'll know those guys." 00:02:13

Anthropic

AI safety company and developer of Claude. Mentioned as a fellow "civilization tech" company — one of the only companies Ben places in the same category as Colossal for planetary-scale impact.

"There's a new term called civilization tech. Anthropic was in it." 00:13:30

4. People Identified

George Church

Harvard geneticist and co-founder of Colossal Biosciences. The scientific anchor of the company whose belief that he could make a woolly mammoth was the founding thesis. Shares Ben's vision for eventually programming living organisms — including trees — into architectural forms.

"George Church thinks he can make a woolly mammoth. And we're pretty sure that that's worth something — that was like the original deck." 00:44:31

Jim Breyer

Venture capitalist, founder of Breyer Capital, and early-stage Colossal investor. Ben specifically named him as the profile of "thoughtful business people" they targeted — investors who understand how full new economies emerge from getting the entire pipeline right.

"Let's go to people like Jim Breyer, let's go to people like Thomas Tull, Mark Walter, people that had built these legacy, large infrastructure plays." 00:42:54

Thomas Tull

Founder of Tulco, former CEO of Legendary Entertainment. Named as a Colossal investor representing the category of long-term, impact-aligned capital from people who have built at scale across entertainment, education, and technology.

"Let's go to people like Thomas Tull, Mark Walter, people that had built these legacy, large infrastructure plays." 00:42:54

Mark Walter

Owner of the Los Angeles Dodgers and co-owner of Chelsea FC; Colossal investor. Represents Ben's deliberate curation of backers who think on decade-long time horizons rather than fund cycle timelines.

"Let's go to people like Jim Breyer, let's go to people like Thomas Tull, Mark Walter." 00:42:54

Avi Loeb

Harvard astrophysicist and head of the Galileo Project focused on UAP scientific research. Ben sits on his UAP scientific advisory board — a data point revealing Ben's cross-disciplinary networks and his proximity to frontier science communities beyond biology.

"I'm on the UAP scientific advisory board for Avi Loeb." 00:58:26

Ashley Vance

Technology journalist and podcaster (formerly Bloomberg). Named as having done Ben's first podcast interview after launching his own show; the two recently reconnected. Noted for extraordinary access journalism including reporting from labs with extreme content.

"I did his podcast and I didn't know him before that. He was awesome. And then we just reconnected like literally in the last week." 00:55:53

Adam Draper

Founder of Boost VC; hosted Ben and George Church on his podcast where both described their shared vision of eventually programming trees to grow in the shape of structures.

"Whose podcast was it? I think it was Adam Draper's podcast where he was like, if you and George could do one thing, what would you do?" 00:56:22

5. Operating Insights

Make the Lab the Physical and Organizational Center of Everything

Colossal designed its entire 85,000-square-foot facility so that all offices, conference rooms, and AI teams wrap around the central lab. This is a deliberate organizational signal: the science is the heart of the company, not the business functions.

"Everything wraps around the lab because the science is the heart of what we do here. All the offices, all the conference rooms, everything, all our AI teams wrap around the lab." 00:03:25

Use One-Way Nano Film for Ambient Culture Reinforcement Without Distraction

Rather than posters or screens visible from inside working areas, Colossal installed one-way nano film so that core values and mission content are visible to people moving through the building (hallways, bathrooms, lunch routes) but invisible and non-distracting to those working inside the lab.

"It's actually a nano film. So we can see it, but it's not distracting... When you're going to lunch, you're going to a meeting, you're going to the bathroom, you're consistently reminded of the things that matter. But when you're working in the lab, it's not distracting." 00:05:44

Capture Every Expert Repetitive Action as Training Data Before Automating It

Rather than immediately automating embryology, Colossal is screen-recording every embryologist action at full resolution — tracking laser position, oocyte position, and DNA extraction volume — to build the dataset needed to eventually automate the process with robotics.

"That's all custom... In the future, that whole process will be automated with robotics... We're looking at the position of the laser, the position of the oocyte, how much DNA is extracted — that entire system, we had to go build that entire system." 00:47:20

Apply Software Project Management Infrastructure to Science Teams

One of Colossal's hardest organizational achievements was getting scientists to work inside tools like Jira and Smartsheets, then connecting those to lab notebooks and proprietary systems through an AI layer — giving management near-real-time visibility into lab progress.

"The hardest thing we've done is reprogram — not stem cells — but scientists who work in things like Jira and Smartsheets... We're connecting those to the lab notebooks and some of our proprietary systems all through an AI layer." 00:48:44

Set Investor Expectations Explicitly on Non-Financial KPIs Before You Take Their Money

Ben told investors from the very first conversation that inspiration must be weighted equally alongside value creation — and only brought in investors who agreed. This pre-commitment prevented misalignment later and allowed the company to pursue culturally expensive but mission-critical programs.

"We told our investors this from day one, that inspiration needs to be as important as value creation. And you need to be on board with that." 00:38:43

6. Overlooked Insights

The Lab-Grown Luxury Animal Fiber Opportunity Is a Billion-Dollar Hidden Revenue Stream

Ben briefly mentioned that a buyer spending billions on a rare, ethically-harvested animal fiber approached Colossal wanting to 5x their domestic supply — and that Colossal is already exploring whether cloning or lab-grown equivalents (similar to their mammoth hair follicle work) could produce it at scale. This was treated as a passing example, but it represents an entirely new industrial category: lab-grown luxury biological materials with existing multi-billion-dollar demand and no current producer. Colossal may be the only company on earth positioned to supply it.

"There's a particular type of fabric that comes from a particular type of animal that's ethically harvested. They literally buy billions of this. They came to us and said, we need to increase this by six X and there's just not enough of these animals... Can we even productionize it where it's like lab-grown meat? We've actually done this — we have hair follicles growing where we've taken elephant stem cells and created follicles so that we can grow mammoth hair. What if you did plates and plates of that and did full warehouses of growing lab-grown equivalent of hair." 00:17:53

Colossal Has the Largest Multi-Species Disease Dataset in the World — and Hasn't Monetized It

In passing, Ben mentioned that Colossal holds the world's largest dataset on elephants and on elephant herpesvirus (EHEV), a herpes variant that kills elephants. This was framed only as context for Astromech's cancer research. But this dataset — spanning multiple species, ancient genomes, and modern endangered species — is a standalone strategic asset. At a time when AI drug discovery companies are competing fiercely for proprietary biological training data, Colossal sits on a unique multi-species genomic and disease dataset that no pharmaceutical company, no AI lab, and no academic institution can replicate. The licensing or partnership value of that data has not been discussed publicly.

"We have the largest dataset on elephants in the entire world. We actually have the largest dataset of multiple species of herpes because EHEV is a herpes vaccine that kills elephants... When you start to look at things like why certain species have invulnerabilities to certain disease states, you know, that affects human healthcare." 00:21:21